Cited by 220Schizophrenia research and treatmentDementia and Cognitive Impairment ResearchMental Health and Psychiatry

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis

Bora, E., Akdede, B. B., Alptekin, K.·2017·Psychological Medicine

Open this paper in CoChat — free account

Abstract

Background: Individuals with schizophrenia are at greater risk for metabolic syndrome (MetS) which is associated with cognitive deficits in the general population. MetS might be potentially an important contributing factor to cognitive impairment in schizophrenia. Method: In the current systematic review and meta-analysis, the findings of 18 studies investigating the association between MetS (and its components) with cognitive impairment in schizophrenia are reviewed. Results: Co-morbidity of MetS ( d = 0.28) and diabetes mellitus ( d = 0.28) were both associated with more severe cognitive deficits in schizophrenia. There was also evidence for a significant relationship between cognitive impairment in schizophrenia and each of the components of MetS including hypertension, dyslipidemia, abdominal obesity and diabetes. Conclusions: MetS is significantly associated with cognitive impairment in schizophrenia and can potentially contribute to functional decline observed in some patients with schizophrenia throughout the course of illness.

Integrity signals

Registry

Crossref · 10.1017/s0033291716003366

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Conducting Meta-Analyses in R with the metafor Package
Viechtbauer, W. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i03 · Cited by 20,464
Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Risk of dementia in diabetes mellitus: a systematic review
Biessels, G. J., Staekenborg, S., Brunner, E., Brayne, C., & Scheltens, P. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70284-2 · Cited by 2,187
Glotaran : A Java -Based Graphical User Interface for the R Package TIMP
Snellenburg, J. J., Laptenok, S. P., Seger, R., Mullen, K. M., & van Stokkum, I. H. M. (2012) · Journal of Statistical Software · doi:10.18637/jss.v049.i03 · Cited by 1,511
Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.
Mcevoy, J., Meyer, J., Goff, D., Nasrallah, H., Davis, S., Sullivan, L., Meltzer, H., Hsiao, J. K., Stroup, T., & Lieberman, J. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.014 · Cited by 1,220
Neurocognition in first-episode schizophrenia: a meta-analytic review.
Mesholam-Gately, R. I., Giuliano, A. J., Goff, K. P., Faraone, S. V., & Seidman, L. J. (2009) · Neuropsychology · doi:10.1037/a0014708 · Cited by 1,130

Show all 56 references

Sorted by citations

Exercise as Medicine for Mental and Substance Use Disorders: A Meta-review of the Benefits for Neuropsychiatric and Cognitive Outcomes
Ashdown-Franks, G., Firth, J., Carney, R., Carvalho, A. F., Hallgren, M., Koyanagi, A., Rosenbaum, S., Schuch, F. B., Smith, L., Solmi, M., et al. (2020) · Sports Medicine · doi:10.1007/s40279-019-01187-6 · Cited by 460
Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review
Solmi, M., Murru, A., Pacchiarotti, I., Undurraga, J., Veronese, N., Fornaro, M., Stubbs, B., Monaco, F., Vieta, E., Seeman, M., et al. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s117321 · Cited by 438
Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia
MacKenzie, N. E., Kowalchuk, C., Agarwal, S. M., Costa-Dookhan, K. A., Caravaggio, F., Gerretsen, P., Chintoh, A. F., Remington, G. J., Taylor, V. H., Müller, D. J., et al. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00622 · Cited by 209
Meta-analysis of longitudinal studies of cognition in bipolar disorder: comparison with healthy controls and schizophrenia
Bora, E., & Özerdem, A. (2017) · Psychological Medicine · doi:10.1017/s0033291717001490 · Cited by 179
Self-citation
Association Between Cardiovascular Risk Factors and Cognitive Impairment in People With Schizophrenia
Hagi, K., Nosaka, T., Dickinson, D., Lindenmayer, J. P., Lee, J., Friedman, J. I., Boyer, L., Han, M., Rashid, N. A. A., & Correll, C. U. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.0015 · Cited by 171
Clinical and metabolic response to vitamin D plus probiotic in schizophrenia patients
Ghaderi, A., Banafshe, H. R., Mirhosseini, N. Z., Moradi, M., Karimi, M., Mehrzad, F., Bahmani, F., & Asemi, Z. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2059-x · Cited by 172
Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art
Harvey, P. D., Bosia, M., Cavallaro, R., Howes, O. D., Kahn, R. S., Leucht, S., Müller, D., Penadés, R., & Vita, A. (2022) · Schizophrenia Research Cognition · doi:10.1016/j.scog.2022.100249 · Cited by 185
Peripheral inflammatory and neurotrophic biomarkers of cognitive impairment in schizophrenia: a meta-analysis
Bora, E. (2019) · Psychological Medicine · doi:10.1017/s0033291719001685 · Cited by 150
Self-citation
Neurobiological Highlights of Cognitive Impairment in Psychiatric Disorders
Morozova, A. Y., Zorkina, Y., Abramova, O. V., Pavlova, O., Ka, P., Soloveva, K., Volkova, M., Alekseeva, P. A., Andryshchenko, A., Kostyuk, G. P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031217 · Cited by 132
Significance of Brain Glucose Hypometabolism, Altered Insulin Signal Transduction, and Insulin Resistance in Several Neurological Diseases
Blázquez, E., Hurtado-Carneiro, V., Ayuso, Y. L. B., Velázquez, E., García‐García, L., Gómez-Oliver, F., Ruiz‐Albusac, J. M., Ávila, J., & Pozo, M. A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.873301 · Cited by 110
Factors associated with brain ageing - a systematic review
Wrigglesworth, J., Ward, P. G. D., Harding, I. H., Nilaweera, D., Wu, Z., Woods, R. L., & Ryan, J. L. (2021) · BMC Neurology · doi:10.1186/s12883-021-02331-4 · Cited by 116
Interactions between metabolic, reward and cognitive processes in appetite control: Implications for novel weight management therapies
Higgs, S., Spetter, M. S., Thomas, J. M., Rotshtein, P., Lee, M. D., Hallschmid, M., & Dourish, C. T. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117736917 · Cited by 108
Obesity, dyslipidemia and brain age in first-episode psychosis
Kolenič, M., Franke, K., Hlinka, J., Matějka, M., Capkova, J., Pausová, Z., Uher, R., Alda, M., Španiel, F., & Hájek, T. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.02.012 · Cited by 98
Effects of Aerobic Exercise on Metabolic Syndrome, Cardiorespiratory Fitness, and Symptoms in Schizophrenia Include Decreased Mortality
Schmitt, A., Maurus, I., Rossner, M. J., Röh, A., Lembeck, M., von Wilmsdorff, M., Takahashi, S., Rauchmann, B., Keeser, D., Hasan, A., et al. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00690 · Cited by 112
Parenting self-compassion: A systematic review and meta-analysis
Jefferson, F. A., Shires, A., & McAloon, J. (2020) · Mindfulness · doi:10.1007/s12671-020-01401-x · Cited by 77
Updating and characterizing neuroanatomical markers in high-risk subjects, recently diagnosed and chronic patients with schizophrenia: A revised coordinate-based meta-analysis
Liloia, D., Brasso, C., Cauda, F., Mancuso, L., Nani, A., Manuello, J., Costa, T., Duca, S., & Rocca, P. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.01.010 · Cited by 71
Metabolic adverse effects of olanzapine on cognitive dysfunction: A possible relationship between BDNF and TNF-alpha
Zhang, C., Fang, X., Yao, P., Mao, Y., Cai, J., Zhang, Y., Chen, M., Fan, W., Tang, W., & Song, L. (2017) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2017.04.014 · Cited by 67
Antipsychotic-Induced Weight Gain in Severe Mental Illness: Risk Factors and Special Considerations
Stogios, N., Humber, B. E., Agarwal, S. M., & Hahn, M. (2023) · Current Psychiatry Reports · doi:10.1007/s11920-023-01458-0 · Cited by 60
Brain insulin action in schizophrenia: Something borrowed and something new
Agarwal, S. M., Caravaggio, F., Costa-Dookhan, K. A., Castellani, L. N., Kowalchuk, C., Asgariroozbehani, R., Graff‐Guerrero, A., & Hahn, M. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.05.010 · Cited by 64
Obesity as a Risk Factor for Accelerated Brain Ageing in First-Episode Psychosis—A Longitudinal Study
McWhinney, S. R., Kolenič, M., Franke, K., Fialová, M., Knytl, P., Matějka, M., Španiel, F., & Hájek, T. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab064 · Cited by 57
The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy
Costa-Dookhan, K. A., Agarwal, S. M., Chintoh, A. F., Tran, V., Stogios, N., Ebdrup, B. H., Sockalingam, S., Rajji, T. K., Remington, G. J., Siskind, D. J., et al. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1698545 · Cited by 60
Obesity and brain structure in schizophrenia – ENIGMA study in 3021 individuals
McWhinney, S. R., Brosch, K., Calhoun, V. D., Crespo‐Facorro, B., Crossley, N. A., Dannlowski, U., Dickie, E. W., Dietze, L. M. F., Donohoe, G. J., du Plessis, S. S., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01616-5 · Cited by 58
Roles of inflammation in intrinsic pathophysiology and antipsychotic drug-induced metabolic disturbances of schizophrenia
Prestwood, T. R., Asgariroozbehani, R., Wu, S., Agarwal, S. M., Logan, R. W., Ballon, J. S., Hahn, M., & Freyberg, Z. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113101 · Cited by 67
Cognitive trajectories following onset of psychosis: a meta-analysis
Watson, A., Harrison, L., Preti, A., Wykes, T., & Cella, M. (2022) · The British Journal of Psychiatry · doi:10.1192/bjp.2022.131 · Cited by 53
Repurposing of Anti-Diabetic Agents as a New Opportunity to Alleviate Cognitive Impairment in Neurodegenerative and Neuropsychiatric Disorders
Chen, Q., Cao, T., Li, N., Zeng, C., Zhang, S., Wu, X., Zhang, B., & Cai, H. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.667874 · Cited by 50
Cognitive impairment in psychiatric diseases: Biomarkers of diagnosis, treatment, and prevention
Wang, Y., Meng, W., Liu, Z., An, Q., & Hu, X. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.1046692 · Cited by 51
A comparative meta-analysis of neurocognition in first-degree relatives of patients with schizophrenia and bipolar disorder
Bora, E. (2017) · European Psychiatry · doi:10.1016/j.eurpsy.2017.06.003 · Cited by 48
Self-citation
Lifespan evolution of neurocognitive impairment in schizophrenia - A narrative review
Fett, A.-K. J., Reichenberg, A., & Velthorst, E. (2022) · Schizophrenia Research Cognition · doi:10.1016/j.scog.2022.100237 · Cited by 49
Pharmacological interventions for prevention of weight gain in people with schizophrenia
Agarwal, S. M., Stogios, N., Ahsan, Z. A., Lockwood, J., Duncan, M. J., Takeuchi, H., Cohn, T. A., Taylor, V. H., Remington, G. J., Faulkner, G., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013337.pub2 · Cited by 56
Chronic smoking and cognition in patients with schizophrenia: A meta-analysis
Coustals, N., Martelli, C., Brunet-Lecomte, M., Petillion, A., Roméo, B., & Benyamina, A. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.03.071 · Cited by 49
Gut microbiota: An intermediary between metabolic syndrome and cognitive deficits in schizophrenia
Zeng, C., Yang, P., Cao, T., Gu, Y., Li, N., Zhang, B., Xu, P., Liu, Y., Luo, Z., & Cai, H. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110097 · Cited by 54
Schizophrenia: A developmental disorder with a risk of non-specific but avoidable decline
Murray, R. M., Bora, E., Modinos, G., & Vernon, A. C. (2022) · Schizophrenia Research · doi:10.1016/j.schres.2022.03.005 · Cited by 47
Self-citation
How and when to treat the most common adverse effects of antipsychotics: Expert review from research to clinical practice
Stahl, S. M., Sy, S., & Maguire, G. A. (2020) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13266 · Cited by 44
Association of Metabolic Syndrome With Neuroimaging and Cognitive Outcomes in the UK Biobank
Qureshi, D., Topiwala, A., Abid, S. U. A., Allen, N. E., Kuźma, E., & Littlejohns, T. J. (2024) · Diabetes Care · doi:10.2337/dc24-0537 · Cited by 42
Long‐term cognitive trajectories and heterogeneity in patients with schizophrenia and their unaffected siblings
Islam, M. A., Habtewold, T. D., van Es, F. D., Quee, P. J., van den Heuvel, E. R., Alizadeh, B. Z., Bruggeman, R., & GROUP Investigators (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12961 · Cited by 41
Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial
Agarwal, S. M., Panda, R., Costa-Dookhan, K. A., MacKenzie, N. E., Treen, Q. C., Caravaggio, F., Hashim, E., Leung, G., Kirpalani, A., Matheson, K., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01338-2 · Cited by 41
Appetite regulating hormones in first-episode psychosis: A systematic review and meta-analysis
Misiak, B., Bartoli, F., Stramecki, F., Samochowiec, J., Lis, M., Kasznia, J., Jarosz, K., & Stańczykiewicz, B. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.05.018 · Cited by 40
Real world sedentary behavior and activity levels in patients with schizophrenia and controls: An ecological momentary assessment study
Strassnig, M., Harvey, P. D., Miller, M., Depp, C. A., & Granholm, E. L. (2020) · Mental health and physical activity · doi:10.1016/j.mhpa.2020.100364 · Cited by 45
Repeated Methylglyoxal Treatment Depletes Dopamine in the Prefrontal Cortex, and Causes Memory Impairment and Depressive-Like Behavior in Mice
Szczepanik, J. C., de Almeida, G. R. L., Cunha, M. P., & Dafré, A. L. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02921-2 · Cited by 39
Cognition and disability in schizophrenia: cognition‐related skills deficits and decision‐making challenges add to morbidity
Harvey, P. D., & Strassnig, M. T. (2019) · World Psychiatry · doi:10.1002/wps.20647 · Cited by 37
Crosstalk between Schizophrenia and Metabolic Syndrome: The Role of Oxytocinergic Dysfunction
Goh, K. K., Chen, C. Y.-A., Wu, T., Chen, C.-H., & Lu, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137092 · Cited by 41
Obesity influences white matter integrity in schizophrenia
Spangaro, M., Mazza, E. B., Poletti, S., Cavallaro, R., & Benedetti, F. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.07.017 · Cited by 36
Sex differences in the association of body mass index with symptoms and cognitive deficits in Chinese patients with chronic schizophrenia
Wei, C. W., Chen, Y. Q., Ma, M., Xiu, M. H., & Zhang, X. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0717-x · Cited by 35
Neurocognitive correlates of metabolic dysregulation in individuals with mood disorders: a systematic review and meta-analysis
Maksyutynska, K., Stogios, N., Prasad, F., Gill, J., Hamza, Z., De, R., Smith, E., Horta, A., Goldstein, B. I., Korczak, D. J., et al. (2024) · Psychological Medicine · doi:10.1017/s0033291724000345 · Cited by 34
Conceptualization and characterization of “primary” and “secondary” cognitive impairment in schizophrenia
Vita, A., Nibbio, G., & Barlati, S. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116126 · Cited by 36
Biopsychology of Physical Activity in People with Schizophrenia: An Integrative Perspective on Barriers and Intervention Strategies
Arnautovska, U., Kesby, J. P., Korman, N., Rebar, A. L., Chapman, J., Warren, N., Rossell, S. L., Dark, F. L., & Siskind, D. J. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s393775 · Cited by 38
Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics
Fang, X., Wang, Y., Chen, Y., Ren, J., & Zhang, C. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s202159 · Cited by 33
Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia
Qubad, M., & Bittner, R. A. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231158152 · Cited by 33
Metabolic syndrome in patients with schizophrenia: Underlying mechanisms and therapeutic approaches (Review)
Manta, A., Georganta, A., Roumpou, A., Zoumpourlis, V., Spandidos, D. A., Rizos, E. N., & Peppa, Μ. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13479 · Cited by 40
The Effects of Online Behavioral Parenting Interventions on Child Outcomes, Parenting Ability and Parent Outcomes: A Systematic Review and Meta-analysis
McAloon, J., & Armstrong, S. M. (2024) · Clinical Child and Family Psychology Review · doi:10.1007/s10567-024-00477-4 · Cited by 31
Relationship of metabolic syndrome and neurocognitive deficits in patients with schizophrenia
Grover, S., Ramachandran, P., Sahoo, S., Gopal, S., Nehra, R., Ganesh, A., Raghavan, V., & Sankaranarayan, A. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.05.023 · Cited by 31
Improving Cognition to Increase Treatment Efficacy in Schizophrenia: Effects of Metabolic Syndrome on Cognitive Remediation's Outcome
Bosia, M., Buonocore, M., Bechi, M., Santarelli, L., Spangaro, M., Cocchi, F., Guglielmino, C., Bianchi, L., Bringheli, S., Bosinelli, F., et al. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00647 · Cited by 30
Metabolic Syndrome and Cognitive Functions in Schizophrenia—Implementation of Dietary Intervention
Adamowicz, K., Mazur, A., Mak, M., Samochowiec, J., & Kucharska–Mazur, J. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00359 · Cited by 32
Higher prevalence of metabolic syndrome and related factors in patients with first-episode psychosis and schizophrenia: a cross-sectional study in Turkey
Şahpolat, M., & Arı, M. (2020) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2020.1815080 · Cited by 30
Brain insulin action: Implications for the treatment of schizophrenia
Agarwal, S. M., Kowalchuk, C., Castellani, L. N., Costa-Dookhan, K. A., Caravaggio, F., Asgariroozbehani, R., Chintoh, A. F., Graff‐Guerrero, A., & Hahn, M. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.05.032 · Cited by 30
The expanding impact of methylglyoxal on behavior-related disorders
de Almeida, G. R. L., Szczepanik, J. C., Selhorst, I., Cunha, M. P., & Dafré, A. L. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110635 · Cited by 29
Dietary Behaviors and Metabolic Syndrome in Schizophrenia Patients
Adamowicz, K., & Kucharska–Mazur, J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020537 · Cited by 29
Altered gut microbiota and systemic immunity in Chinese patients with schizophrenia comorbid with metabolic syndrome
Ling, Z., Lan, Z., Cheng, Y., Liu, X., Li, Z., Yu, Y., Wang, Y., Shao, L., Zhu, Z., Gao, J., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05533-9 · Cited by 27
A systematic review and meta-analysis of the effect of clozapine on cognitive functions in patients with treatment-resistant schizophrenia
Cheuk, N. K. W., Tse, W., Tsui, H. K. H., Ma, C. F., Chun, J., Chung, A. K. K., & Chan, S. K. W. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2023.09.027 · Cited by 27
Key role for lipids in cognitive symptoms of schizophrenia
Maas, D. A., Martens, M. B., Priovoulos, N., Zuure, W. A., Homberg, J. R., Nait‐Oumesmar, B., & Martens, G. J. M. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-01084-x · Cited by 29
Factors influencing the outcome of integrated therapy approach in schizophrenia: A narrative review of the literature
Giordano, G. M., Brando, F., Pezzella, P., Angelis, M. D., Mucci, A., & Galderisi, S. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.970210 · Cited by 28
Advanced Brain-Age in Psychotic Psychopathology: Evidence for Transdiagnostic Neurodevelopmental Origins
Demro, C., Shen, C., Hendrickson, T. J., Arend, J. L., Disner, S. G., & Sponheim, S. R. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.872867 · Cited by 24
Erythropoietin for Cognitive Deficits Associated with Schizophrenia, Bipolar Disorder, and Major Depression: A Systematic Review
Li, X.-B., Zheng, W., Ning, Y.-P., Cai, D.-B., Yang, X.-H., Ungvari, G. S., Ng, C. H., Wang, C., & Xiang, Y. (2017) · Pharmacopsychiatry · doi:10.1055/s-0043-114670 · Cited by 25
Treating cognitive impairment in schizophrenia with GLP-1RAs: an overview of their therapeutic potential
Flintoff, J. M., Kesby, J. P., Siskind, D. J., & Burne, T. H. J. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1951702 · Cited by 25
Diabetes mellitus, cognitive deficits and serum BDNF levels in chronic patients with schizophrenia: A case-control study
Li, S., Chen, D., Xiu, M., Li, J., & Zhang, X. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.12.035 · Cited by 24
Shared and unique characteristics of metabolic syndrome in psychotic disorders: a review
Saccaro, L. F., Aimo, A., Panichella, G., & Sentissi, O. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1343427 · Cited by 30
Neurological soft signs and cognition in the late course of chronic schizophrenia: a longitudinal study
Herold, C. J., Duval, C. Z., & Schröder, J. (2020) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01138-7 · Cited by 23
Use of the RBANS to Evaluate Cognition in Patients with Schizophrenia and Metabolic Syndrome: a Meta-Analysis of Case-Control Studies
Zheng, W., Jiang, W., Zhang, X., Cai, D.-B., Sun, J., Yin, F., Ren, P., Zhao, M., Wu, H., Xiang, Y., et al. (2021) · Psychiatric Quarterly · doi:10.1007/s11126-021-09889-9 · Cited by 23
Schizophrenia and obesity: May the gut microbiota serve as a link for the pathogenesis?
Wu, H., Liu, Y., Wang, J., Chen, S., Xie, L., & Wu, X. (2023) · iMeta · doi:10.1002/imt2.99 · Cited by 24
The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial
Li, M., Liu, Y., Qiu, Y., Zhang, J., Zhang, Y., Zhao, Y., Jia, Q., & Li, J. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113899 · Cited by 21
Emergency medical care of patients with psychiatric disorders - challenges and opportunities: Results of a multicenter survey
Schick, B., Mayer, B., Jäger, M., Jungwirth, B., Barth, E., Eble, M., Sponholz, C., Muth, C.-M., & Schönfeldt‐Lecuona, C. (2022) · BMC Emergency Medicine · doi:10.1186/s12873-022-00722-5 · Cited by 21
Assessment of the Association Between Cigarette Smoking and Cognitive Performance in Patients With Schizophrenia-Spectrum Disorders: A Case-Control Study
Stramecki, F., Kotowicz, K., Piotrowski, P., Frydecka, D., Rymaszewska, J., Beszłej, J. A., Samochowiec, J., Jabłoński, M., Wroński, M., Moustafa, A. A., et al. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00642 · Cited by 20
Clinical Correlates of Insulin Resistance in Chronic Schizophrenia: Relationship to Negative Symptoms
Soontornniyomkij, V., Lee, E. E., Jin, H., Martin, A., Daly, R., Liu, J., Tu, X., Eyler, L., & Jeste, D. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00251 · Cited by 19
Definition, assessment and treatment of cognitive impairment associated with schizophrenia: expert opinion and practical recommendations
Vita, A., Barlati, S., Cavallaro, R., Mucci, A., Riva, M. A., Rocca, P., Rossi, A., & Galderisi, S. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1451832 · Cited by 28
Neuregulin 3 rs10748842 polymorphism contributes to the effect of body mass index on cognitive impairment in patients with schizophrenia
Zhou, Y., Li, Y., Meng, Y., Wang, J., Wu, F., Ning, Y., Li, Y., Cassidy, R. M., Li, Z., & Zhang, X. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0746-5 · Cited by 19
Mega-analysis of association between obesity and cortical morphology in bipolar disorders: ENIGMA study in 2832 participants
McWhinney, S. R., Abé, C., Alda, M., Benedetti, F., Bøen, E., Bonnín, C. D. M., Borgers, T., Brosch, K., Canales-Rodríguez, E. J., Cannon, D. M., et al. (2023) · Psychological Medicine · doi:10.1017/s0033291723000223 · Cited by 18
Get up! Functional mobility and metabolic syndrome in chronic schizophrenia: Effects on cognition and quality of life
Cuoco, F., Agostoni, G., Lesmo, S., Sapienza, J., Buonocore, M., Bechi, M., Martini, F., Ferri, I., Spangaro, M., Bigai, G., et al. (2022) · Schizophrenia Research Cognition · doi:10.1016/j.scog.2022.100245 · Cited by 17
Functional Connectome Hierarchy in Schizotypy and Its Associations With Expression of Schizophrenia-Related Genes
Dong, D., Wang, Y., Zhou, F., Chang, X., Qiu, J., Feng, T., He, Q., Lei, X., & Chen, H. (2023) · Schizophrenia Bulletin · doi:10.1093/schbul/sbad179 · Cited by 17
The correlation between metabolic syndrome and neurocognitive and social cognitive performance of patients with schizophrenia
Chen, S., Xia, X., Deng, C., Wu, X., Han, Z., Tao, J., & Wu, X. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.112941 · Cited by 17
The Candidate Schizophrenia Risk Gene Tmem108 Regulates Glucose Metabolism Homeostasis
Yu, J., Liao, X., Zhong, Y., Wu, Y., Lai, X., Jiao, H., Yan, M., Zhang, Y., Ma, C., & Wang, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.770145 · Cited by 17
Choroidal structural analysis in ultra-high risk and first-episode psychosis
Demirlek, C., Ataş, F., Yalınçetin, B., Gurbuz, M. S., Cesim, E., Demir, M., Ozbek, S. U., Süt, E., Baykara, B., Akdede, B. B., et al. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.02.016 · Cited by 16
Self-citation
The Kraepelian concept of schizophrenia: Dying but not yet dead
Murray, R. M., & Quattrone, D. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.12.005 · Cited by 15
Neurocognitive correlates of the varied domains of outcomes at 20 year follow-up of first-episode psychosis
Cuesta, M. J., Sánchez-Torres, A. M., Moreno-Izco, L., de Jalón, E. G., Gil‐Berrozpe, G. J., Zarzuela, A., Peralta, V., Ballesteros, A., Fañanás, L., Hernández, R., et al. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114933 · Cited by 17
Validity and correlates of the International Physical Activity Questionnaire in first‐episode psychosis
Vancampfort, D., Binder, M. D., Myin‐Germeys, I., Rosenbaum, S., Stubbs, B., Damme, T. V., & Probst, M. (2017) · Early Intervention in Psychiatry · doi:10.1111/eip.12521 · Cited by 16
Transdiagnostic neurocognitive deficits in patients with type 2 diabetes mellitus, major depressive disorder, bipolar disorder, and schizophrenia: A 1-year follow-up study
Correa‐Ghisays, P., Sánchez‐Ortí, J. V., Balanzá‐Martínez, V., Selva‐Vera, G., Vila‐Francés, J., Magdalena‐Benedito, R., Víctor, V. M., Escribano‐López, I., Hernández‐Mijares, A., Vivas‐Lalinde, J., et al. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.074 · Cited by 15
Metabolic disturbances, hemoglobin A1c, and social cognition impairment in Schizophrenia spectrum disorders
Tang, S. X., Oliver, L. D., Hänsel, K., DeRosse, P., John, M., Khairullah, A., Gold, J. M., Buchanan, R. W., Voineskos, A. N., & Malhotra, A. K. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02002-z · Cited by 15
Association of clinical symptoms and cardiometabolic dysregulations in patients with schizophrenia spectrum disorders
Zhao, C., Habtewold, T. D., Naderi, E., Liemburg, E. J., GROUP Investigators, Bruggeman, R., & Alizadeh, B. Z. (2023) · European Psychiatry · doi:10.1192/j.eurpsy.2023.2477 · Cited by 14
Intestinal permeability biomarkers in patients with schizophrenia: Additional support for the impact of lifestyle habits
González-Blanco, L., Santo, F. D., García‐Portilla, M. P., Alfonso, M., Hernández, C., Sánchez-Autet, M., Anmella, G., Amoretti, S., Safont, G., Martín‐Hernández, D., et al. (2024) · European Psychiatry · doi:10.1192/j.eurpsy.2024.1765 · Cited by 15
Abnormal corneal nerve morphology and brain volume in patients with schizophrenia
Ponirakis, G., Ghandi, R., Ahmed, A. A., Gad, H., Petropoulos, I. N., Khan, A., Elsotouhy, A., Vattoth, S., Alshawwaf, M. K. M., Khoodoruth, M. A. S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-05609-w · Cited by 14
Longitudinal changes of cognitive function and its relationship with subdomains of negative symptoms in patients with adult-onset first-episode schizophrenia: A 4-year follow up study
Chan, S. K. W., Liao, Y., Hui, C. L. M., Wong, T. Y., Suen, Y. N., Chang, W. C., Lee, E. H. M., & Chen, E. Y. H. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2023.01.004 · Cited by 15
Cognitive deficits among people with schizophrenia and prediabetes or diabetes
John, A. P., Mya, T., & Haywood, D. (2023) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13627 · Cited by 13
Association of cytokines levels, psychopathology and cognition among CR-TRS patients with metabolic syndrome
Dong, Y., Zhu, M., Li, Y., Liu, N., Wang, X., Yang, B., Li, S., & Li, Z. (2024) · Schizophrenia · doi:10.1038/s41537-024-00469-x · Cited by 13
Multi-omics analysis reveals the impact of gut microbiota on antipsychotic-induced weight gain in schizophrenia
Liu, Y., Wu, H., Liu, B., Chen, S., Huang, L., Liu, Z., Wang, J., Xie, L., & Wu, X. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.06.040 · Cited by 15
Serum levels of β-hydroxybutyrate and pyruvate, metabolic changes and cognitive function in patients with schizophrenia during antipsychotic treatment: a preliminary study
Huang, Y., Lin, P., Lee, Y., Hung, C., Hsu, S., Wu, C., & Wang, L. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s157055 · Cited by 13
The Association Between Metabolic Disturbance and Cognitive Impairments in Early-Stage Schizophrenia
Peng, X., Hei, G., Li, R., Yang, Y., Liu, C., Xiao, J., Long, Y., Shao, P., Huang, J., Zhao, J., et al. (2021) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2020.599720 · Cited by 13
Identification of potential blood biomarkers for early diagnosis of schizophrenia through RNA sequencing analysis
Li, Z., Li, X., Jin, M., Liu, Y., He, Y., Jia, N., Cui, X., Liu, Y., Hu, G., & Yu, Q. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.01.003 · Cited by 14
Glucose dysregulation in antipsychotic-naive first-episode psychosis: in silico exploration of gene expression signatures
Lee, J., Xue, X., Au, E., McIntyre, W. B., Asgariroozbehani, R., Panganiban, K. J., Tseng, G. C., Papoulias, M., Smith, E., Monteiro, J., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-023-02716-8 · Cited by 13
A Review of Switching Strategies for Patients with Schizophrenia Comorbid with Metabolic Syndrome or Metabolic Abnormalities
Liao, X., Ye, H., & Si, T. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s294521 · Cited by 13
Metabolic Syndrome Causing Cognitive Impairment in Patients With Schizophrenia: A Systematic Review
Saxena, A., Patel, D. N., Ayesha, I. E., Monson, N. R., Klair, N., Patel, U. P., & Khan, S. (2023) · Cureus · doi:10.7759/cureus.47587 · Cited by 12
Gut microbiome and metabolism alterations in schizophrenia with metabolic syndrome severity
Zhao, H., Zhu, G., Zhu, T., Ding, B., Xu, A., Gao, S., Chao, Y., Li, N., Chen, Y., Wang, Z., et al. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05969-9 · Cited by 13

Authors: Bora, E., Akdede, B. B., & Alptekin, K.
Affiliations: The University of Melbourne (AU)
Dokuz Eylül University (TR)
Corresponding author: Bora, E.
ORCID: Bora, E.
Akdede, B. B.
Venue: Psychological Medicine
Publisher: Cambridge University Press (CUP)
Published: 2016-12-29
Volume: 47
Issue: 6
Pages: 1030-1040
ISSN: 0033-2917 (ISSN-L)
1469-8978
DOI: 10.1017/s0033291716003366
OpenAlex: W2563404365
Cited by: 219
References: 56
Citations by year: 2026: 11 · 2025: 23 · 2024: 29 · 2023: 22 · 2022: 34 · 2021: 28 · 2020: 24 · 2019: 23 · 2018: 15 · 2017: 9
FWCI: 2.24
Type: journal article
Language: en
Open access: closed
Licence: www.cambridge.org/core/terms (unspecified)
Locations: Psychological Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Türkiye Bilimsel ve Teknolojik Araştırma Kurumu
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Keywords: schizophrenia, cognitive impairment, metabolic syndrome, diabetes mellitus, hypertension, dyslipidemia, abdominal obesity, functional decline, comorbidities
MeSH terms: Diabetes Mellitus, Humans, Schizophrenia, Comorbidity, Metabolic Syndrome, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks